Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

India Busts Another Western Drug Patent

by Jean-François Tremblay
November 12, 2012 | A version of this story appeared in Volume 90, Issue 46

India’s Intellectual Property Appellate Board has sided with a local nonprofit organization and decided that Roche’s patent on the hepatitis drug Pegasys is not valid in India. The board’s decision reverses a 2007 ruling by the Controller General of Patents, Designs & Trademarks. The appellate board explained that the Roche drug lacks inventiveness because anyone familiar with the scientific literature when Roche patented it could have invented an identical treatment. Known generically as PEGylated interferon alfa-2a, Pegasys is an antiviral that uses polyethylene glycol to enhance the half-life of interferon.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.